Qinfeng Li1,2,3, Chao Li3, Abdallah Elnwasany3, Gaurav Sharma4, Yu A An5, Guangyu Zhang, Waleed M Elhelaly3, Jun Lin1,2, Yingchao Gong1,2, Guihao Chen3, Meihui Wang1,2, Shangang Zhao5, Chongshan Dai3, Charles D Smart3, Juan Liu6, Xiang Luo3, Yingfeng Deng5, Lin Tan7, Shuang-Jie Lv8, Shawn M Davidson9, Jason W Locasale6, Philip L Lorenzi7, Craig R Malloy4,10,11, Thomas G Gillette3, Matthew G Vander Heiden9,12, Philipp E Scherer5, Luke I Szweda3, Guosheng Fu1,2, Zhao V Wang3. 1. Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, China (Q.L., J.Lin, Y.G., M.W., G.F.). 2. Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Zhejiang, China (Q.L., J.Lin, Y.G., M.W., G.F.). 3. Division of Cardiology, Department of Internal Medicine (Q.L., C.L., A.E., G.Z., W.M.E., G.C., C.D., C.D.S., X.L., T.G.G., L.I.S., Z.V.W.), University of Texas Southwestern Medical Center, Dallas. 4. Advanced Imaging Research Center (G.S., C.R.M.), University of Texas Southwestern Medical Center, Dallas. 5. Touchstone Diabetes Center, Department of Internal Medicine (Y.A.A., S.Z., Y.D., P.E.S.), University of Texas Southwestern Medical Center, Dallas. 6. Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC (J.Liu, J.W.L.). 7. Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston (L.T., P.L.L.). 8. State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China (S-J.L.). 9. Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge (S.M.D., M.G.V.H.). 10. Department of Internal Medicine (C.R.M.), University of Texas Southwestern Medical Center, Dallas. 11. Department of Radiology (C.R.M.), University of Texas Southwestern Medical Center, Dallas. 12. Dana-Farber Cancer Institute, Boston, MA (M.G.V.H.).
Abstract
BACKGROUND: Metabolic remodeling precedes most alterations during cardiac hypertrophic growth under hemodynamic stress. The elevation of glucose utilization has been recognized as a hallmark of metabolic remodeling. However, its role in cardiac hypertrophic growth and heart failure in response to pressure overload remains to be fully illustrated. Here, we aimed to dissect the role of cardiac PKM1 (pyruvate kinase muscle isozyme 1) in glucose metabolic regulation and cardiac response under pressure overload. METHODS: Cardiac-specific deletion of PKM1 was achieved by crossing the floxed PKM1 mouse model with the cardiomyocyte-specific Cre transgenic mouse. PKM1 transgenic mice were generated under the control of tetracycline response elements, and cardiac-specific overexpression of PKM1 was induced by doxycycline administration in adult mice. Pressure overload was triggered by transverse aortic constriction. Primary neonatal rat ventricular myocytes were used to dissect molecular mechanisms. Moreover, metabolomics and nuclear magnetic resonance spectroscopy analyses were conducted to determine cardiac metabolic flux in response to pressure overload. RESULTS: We found that PKM1 expression is reduced in failing human and mouse hearts. It is important to note that cardiomyocyte-specific deletion of PKM1 exacerbates cardiac dysfunction and fibrosis in response to pressure overload. Inducible overexpression of PKM1 in cardiomyocytes protects the heart against transverse aortic constriction-induced cardiomyopathy and heart failure. At the mechanistic level, PKM1 is required for the augmentation of glycolytic flux, mitochondrial respiration, and ATP production under pressure overload. Furthermore, deficiency of PKM1 causes a defect in cardiomyocyte growth and a decrease in pyruvate dehydrogenase complex activity at both in vitro and in vivo levels. CONCLUSIONS: These findings suggest that PKM1 plays an essential role in maintaining a homeostatic response in the heart under hemodynamic stress.
BACKGROUND: Metabolic remodeling precedes most alterations during cardiac hypertrophic growth under hemodynamic stress. The elevation of glucose utilization has been recognized as a hallmark of metabolic remodeling. However, its role in cardiac hypertrophic growth and heart failure in response to pressure overload remains to be fully illustrated. Here, we aimed to dissect the role of cardiac PKM1 (pyruvate kinase muscle isozyme 1) in glucose metabolic regulation and cardiac response under pressure overload. METHODS: Cardiac-specific deletion of PKM1 was achieved by crossing the floxed PKM1 mouse model with the cardiomyocyte-specific Cre transgenic mouse. PKM1 transgenic mice were generated under the control of tetracycline response elements, and cardiac-specific overexpression of PKM1 was induced by doxycycline administration in adult mice. Pressure overload was triggered by transverse aortic constriction. Primary neonatal rat ventricular myocytes were used to dissect molecular mechanisms. Moreover, metabolomics and nuclear magnetic resonance spectroscopy analyses were conducted to determine cardiac metabolic flux in response to pressure overload. RESULTS: We found that PKM1 expression is reduced in failing human and mouse hearts. It is important to note that cardiomyocyte-specific deletion of PKM1 exacerbates cardiac dysfunction and fibrosis in response to pressure overload. Inducible overexpression of PKM1 in cardiomyocytes protects the heart against transverse aortic constriction-induced cardiomyopathy and heart failure. At the mechanistic level, PKM1 is required for the augmentation of glycolytic flux, mitochondrial respiration, and ATP production under pressure overload. Furthermore, deficiency of PKM1 causes a defect in cardiomyocyte growth and a decrease in pyruvate dehydrogenase complex activity at both in vitro and in vivo levels. CONCLUSIONS: These findings suggest that PKM1 plays an essential role in maintaining a homeostatic response in the heart under hemodynamic stress.
Authors: Yuan Wang; Yuannyu Zhang; Guanqiao Ding; Herman I May; Jian Xu; Thomas G Gillette; Hang Wang; Zhao V Wang Journal: Am J Physiol Heart Circ Physiol Date: 2017-08-19 Impact factor: 4.733
Authors: Hong Ma; Shuo Yu; Xiaojing Liu; Yingao Zhang; Thomas Fakadej; Ziqing Liu; Chaoying Yin; Weining Shen; Jason W Locasale; Joan M Taylor; Li Qian; Jiandong Liu Journal: Circulation Date: 2019-04-02 Impact factor: 29.690
Authors: Yingfeng Deng; Zhao V Wang; Ruth Gordillo; Yi Zhu; Aktar Ali; Chen Zhang; Xiaoding Wang; Mengle Shao; Zhuzhen Zhang; Puneeth Iyengar; Rana K Gupta; Jay D Horton; Joseph A Hill; Philipp E Scherer Journal: Mol Metab Date: 2018-03-02 Impact factor: 7.422
Authors: Xiaoding Wang; Guangyu Zhang; Subhajit Dasgupta; Erica L Niewold; Chao Li; Qinfeng Li; Xiang Luo; Lin Tan; Anwarul Ferdous; Philip L Lorenzi; Beverly A Rothermel; Thomas G Gillette; Christopher M Adams; Philipp E Scherer; Joseph A Hill; Zhao V Wang Journal: Circ Res Date: 2022-05-16 Impact factor: 23.213
Authors: Hannah R Foster; Thuong Ho; Evgeniy Potapenko; Sophia M Sdao; Shih Ming Huang; Sophie L Lewandowski; Halena R VanDeusen; Shawn M Davidson; Rebecca L Cardone; Marc Prentki; Richard G Kibbey; Matthew J Merrins Journal: Elife Date: 2022-08-23 Impact factor: 8.713